Search
Dexchlorpheniramine
go.drugbank.com/drugs/DB13679InvestigationalIt is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells. … Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine.
Beraprost
go.drugbank.com/drugs/DB05229InvestigationalBeraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Categories: Prostaglandins ICYNK-001
go.drugbank.com/drugs/DB15722InvestigationalCYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
99mTc-glucarate
go.drugbank.com/drugs/DB05810Investigational99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Mephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnMephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. … These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.
AEG35156
go.drugbank.com/drugs/DB06184InvestigationalAEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. … This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis.
Flurothyl
go.drugbank.com/drugs/DB08969ApprovedWithdrawnFlurothyl is a convulsant primarily used in experimental animals. It was formerly used to induce convulsions as a alternative to electroshock therapy.
Otamixaban
go.drugbank.com/drugs/DB06635InvestigationalOtamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.